Evidence map›Paper›PMID 30559784›Full record

ArticlePakistan journal of medical sciences

The effectiveness of oral antiviral (Sofosbuvir/Ledipasvir) in treating children with HCV infection.

Ban Adil Alkaaby, Abd El-Salam Al-Ethawi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pakistan journal of medical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. [Use of sofosbuvir-based regimens in the treatment of adolescents and children with chronic hepatitis C].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ban Adil AlkaabyBan Adil Al-Kaaby, MRCPCh, FICMS-Ped., Senior Lecturer, Paediatrics Department, Al-Mustansiryah Medical College, Specialist Pediatrician at Central Child Teaching Hospital & Gastroenterology and Hepatology Center, Baghdad, Iraq.
Abd El-Salam Al-EthawiAbd El-Salam Al-Ethawi, Senior Lecturer, Pediatrics Department, Al-Mustansiryah Medical College, Paediatrics Cardiologist at Ibn Al-Bittar Center for Cardiac Surgery and Central Child Teaching Hospital, Baghdad, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo determine the efficacy of (Sofosbuvir/ledipasvir) in treating children with HCV infection.

methodsThis study was conducted at Gastroenterology, Hepatology Center /Pediatrics department and the Central Child Teaching Hospital, Baghdad / Iraq from April 2017 to January 2018. Patients with positive HCV PCR, aged 7 to 18 years were enrolled. History, clinical examinations and investigations were conducted. HCV genotyping was done (if affordable). Sofosbuvir/Ledipasvir was given to all patients once daily. Ribavirin was added for INF-experienced patients or with established cirrhosis. Follow up with liver function and renal function and PCR was done at 12 weeks (end of treatment); then after 12 weeks post treatment (SVR12). Total duration of therapy was 12 weeks, extended to 24 in cases with established cirrhosis. Computer program SPSS version 20 was used for data analysis.

resultsThe number of patients was 22, with mean age of 12.5 years, 14 boys (63.6%), and 8 girls (36.4%). Genotype 1 was the dominant type (75%). SVR 12 was achieved in 20 patients (90.9%), the remaining two (9.1%) had partial virological response. HBV co-infection was found in five cases; they were kept on Entecavir during the course of treatment. All achieved SVR12 for HCV with decrease in titer of HBV. Even INF-experienced patients (7 patients 31.8%) were responsive with SVR12. The treatment was well tolerated.

conclusionSofosbuvir/ledipasvir is effective in treating HCV in children, and is well tolerated.

Indexed as

ChildrenDirect acting antiviralsHepatitis C virusPediatricsSofosbuvir/ledipasvir

Identifiers

PMID30559784
PMCPMC6290209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.